Reports and general public notices have emerged in a number of EU Member States in recent years, alerting consumers about new opioids mis-marketed as phony medicines, such as oxycodone tablets containing nitazenes. Also, we see a trend of drop in value from 2014 to 2019 of some opioids which include heroin, oxycodone, and fentanyl, which may bri

Article Under Review